Pharmasaga Company Limited
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Currently, Pharmasaga has two Pdia4 inhibitors, PS-001 and PS-002, for type 2 diabetes (T2D) and type 1 diabetes (T1D), respectively. Their pre-clinical studies were completed in 2021.
US FDA approved the application of investigation drug (IND), PS-001. W
US FDA approved the application of investigation drug (IND), PS-001. W
Founded Year
2021
Unified Business No.
83379922
Status
Active
Number of Employees
14
Total Paid-in
Capital
535,365,800 (NT$)
Location of Company
Taiwan
, Taipei City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Pharmasaga is a spin-off of Academia Sinica and was founded in Jan 2021. Our core technology is a drug discovery platform composed of molecular docking, chemistry and biology for drug discovery, developed by Dr Wen-Chin Yang, Academia Sinica. With this platform, we developed first-in-class Pdia4 inhibitors for diabetes. The Pdia4 inhibitors can be used as a brand-new beta cell-centric approach to reducing beta cell failure and, in turn, diabetes. More importantly, the Pdia4 inhibitors can reverse diabetes alone and in combination with metformin.
